Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon
- 25 Downloads
Patients taking oral anticoagulants (OACs) currently represent one-third of all patients treated for epistaxis and an upward trend is expected. New direct oral anticoagulants (DOACs) have been on the market for approximately 10 years. DOACs are favoured over Vitamin K-Antagonists (VKAs) in the current guidelines. There are barely studies that investigate the impact of DOACs on patients with epistaxis. A retrospective study was performed analysing all patients who had stationary treatment for epistaxis from 01.01.2011 to 01.01.2018 in a tertiary care centre. In a total of 466 patients, 46.1% were on OACs. The main indication was atrial fibrillation (AF, 67.4%).The number of DOACs taken surpassed that of the VKAs during the past 2 years. The length of hospital stay was significantly longer in the phenprocoumon group (3 ± 0.2 days) in comparison to both the rivaroxaban (2.3 ± 0.1) and the apixaban (2.2 ± 0.1) groups (p = 0.005). Posterior epistaxis occurred more frequently in the phenprocoumon group (10.8%) than in the rivaroxaban (0%) and apixaban (0%) groups (p = 0.03). A correlation between CHA2DS2–VASc score (risk score for apoplexy in patients with AF, p = 0.01), HAS-BLED score (score for assessment of major bleeding in patients taking anticoagulants with AF, p = 0.006), and length of hospital stay (p = 0.002) with recurrence of epistaxis was found. Shorter hospital stays and exclusively anterior bleeding was noted in AF patients taking rivaroxaban and apixaban, whereas AF patients taking phenprocoumon stayed in hospital longer and had more posterior bleeding.
KeywordsEpistaxis Rivaroxaban Apixaban Phenprocoumon Atrial fibrillation
This project was funded entirely by the Department of Otorhinolaryngology of the Sana Kliniken Leipziger Land, Germany.
Compliance with ethical standards
Conflict of interest
All authors have indicated that they have no conflict of interest.
- 2.Destatis. Diagnosedaten der Krankenhäuser ab 2000 (Eckdaten der vollstationären Patienten und Patientinnen) (2018) Gesundheitsberichterstattung des Bundes. http://www.gbe-bund.de/
- 3.Statistics NHe (2016) http://content.digital.nhs.uk/hes
- 4.Destatis (2015) Sterbefälle, Sterbeziffern (je 100.000 Einwohner, altersstandardisiert). http://www.gbe-bund.de/
- 10.FDA (2010) Approval Dabigatran. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512orig1s000toc.cfm
- 11.FDA (2011) Approval Rivaroxaban. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/202439s000ltr.pdf
- 12.FDA (2012) Approval Apixaban. https://www.fda.gov/downloads/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm333723.pdf
- 13.Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M et al (2015) Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial. Circulation 132(8):624–632CrossRefPubMedGoogle Scholar
- 21.Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33(21):2719–2747CrossRefPubMedGoogle Scholar